Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive a ...

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive a ...

Transitioned from a clinical-stage entity to a commercially minded organization through a strategic restructuring and leadership strengthening in late 2025. Performance in 2025 was driven by Rytelo's first full year of commercial availability, establishing a footprint of approximately 1,300 prescribing accounts. Strategic focus has shifted squarely to the second-line lower-risk MDS setting, where management believes Rytelo offers the most significant clinical impact and market opportunity. Market dy ...

Cross-functional account management incorporating ASH 2025 data, including proactive discussion of cytopenias and messaging positioning RYTELO as a standard-of-care option for appropriate second-line patients “regardless of their RS status.”Increased investment in marketing channels the company считает most effective, including digital, non-personal promotion, and third-party educational platforms—what management referred to as a “3D surround sound” approach.Targeted engagement with high-volume community ac ...

Geron (NasdaqGS:GERN) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Company ParticipantsAhmed ElNawawi - EVP and Chief Commercial OfficerCorinne Johnson - Managing DirectorDawn Schottlandt - Senior VP, Investor Relations, and Corporate AffairsHarout Semerjian - President and CEOJoseph Eid - EVP of Research and DevelopmentMichelle Robertson - EVP, CFO and, TreasurerConference Call ParticipantsEmily Bodnar - Biotech Equity Research AnalystGil Blum - Senior Biotech AnalystStephen Willey - Managing Direct ...

Geron (NasdaqGS:GERN) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Speaker8Please be advised that today's conference is being recorded. I would now like to turn the call over to Dawn Schottlandt, Senior Vice President, Investor Relations and Corporate Affairs. You may begin.Speaker2Good morning, everyone. Welcome to the Geron Corporation fourth quarter 2025 earnings conference call. Before we begin, please note that during the course of this presentation and question and answer session, we will be ma ...

Exhibit 99.1 Achieved $48 million and $184 million in RYTELO® (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025, within the previous guidance range Reiterated 2026 RYTELO net product revenue and total operating expenses expected in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Ended 2025 with cash, cash equivalents, restricted cash and marketable securities of roughly ...

Achieved $48 million and $184 million in RYTELO® (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025, within the previous guidance range Reiterated 2026 RYTELO net product revenue and total operating expenses expected in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Ended 2025 with cash, cash equivalents, restricted cash and marketable securities of roughly $401 million ...

Geron Corporation (NASDAQ:GERN) is one of the 13 Best American Penny Stocks to Invest In. On January 29, TD Cowen analyst Tara Bancroft reduced the firm’s price target on Geron Corporation (NASDAQ:GERN) from $4 to $3 and maintained a Buy rating on the stock. This update comes before the company’s fourth-quarter results, which the company plans to report on February 25. In other news, on January 12, Geron Corporation (NASDAQ:GERN) shared its financial guidance for 2026. The company expects RYTELO net prod ...

FOSTER CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to present at the following investor conferences: TD Cowen 46th Annual Healthcare ConferenceFireside Chat on Monday, March 2 at 1:10 p.m. ET in Boston, MABarclays 28th Annual Global Healthcare ConferenceFireside Chat on Tuesday, March 10 at 10:30 a. ...